Kalvista制药公司宣布,其针对2至11岁遗传性血管性水肿患儿的Konfident-Kid临床试验取得积极进展。公司计划于2026年第三季度向监管机构提交口服药物Sebetralstat的新药申请。该试验旨在评估Sebetralstat在儿科患者群体中的安全性和有效性,若获批将成为该年龄段首款口服预防药物。
Kalvista制药公司宣布,其针对2至11岁遗传性血管性水肿患儿的Konfident-Kid临床试验取得积极进展。公司计划于2026年第三季度向监管机构提交口服药物Sebetralstat的新药申请。该试验旨在评估Sebetralstat在儿科患者群体中的安全性和有效性,若获批将成为该年龄段首款口服预防药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.